PGGM Investments Sells 7,638 Shares of argenx SE (NASDAQ:ARGX)

PGGM Investments lessened its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 11.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,771 shares of the company's stock after selling 7,638 shares during the quarter. PGGM Investments owned approximately 0.09% of argenx worth $34,914,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Whipplewood Advisors LLC bought a new stake in argenx in the fourth quarter worth approximately $37,000. Global Retirement Partners LLC increased its holdings in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after acquiring an additional 48 shares during the period. Jones Financial Companies Lllp raised its position in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after buying an additional 61 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after purchasing an additional 21 shares in the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in argenx during the 4th quarter valued at $66,000. 60.32% of the stock is owned by institutional investors.

argenx Trading Up 1.5 %

NASDAQ ARGX traded up $9.23 on Monday, reaching $614.19. The stock had a trading volume of 292,081 shares, compared to its average volume of 285,821. argenx SE has a 1 year low of $349.86 and a 1 year high of $678.21. The business has a 50 day moving average price of $638.20 and a 200 day moving average price of $596.88. The company has a market capitalization of $37.32 billion, a price-to-earnings ratio of -697.94 and a beta of 0.59.

Remove Ads

argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million during the quarter, compared to analysts' expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. On average, analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ARGX. Sanford C. Bernstein upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a report on Monday. HC Wainwright upped their target price on shares of argenx from $717.00 to $720.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Citigroup reiterated an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Robert W. Baird increased their price target on argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a report on Tuesday, March 4th. Finally, Deutsche Bank Aktiengesellschaft upgraded argenx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.